At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 97 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder
In Brief
A Phase 4 clinical trial evaluating Atomoxetine and Placebo for Autistic Disorder and Attention Deficit Disorder With Hyperactivity. Completed, enrolled 97 participants across 8 sites.
Detailed Summary
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNetherlands
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartOct 2006
Primary CompletionMay 2008
Study CompletionOct 2008
TodayJul 2026
First PostedSep 26, 2006
Enrollment StartOct 1, 2006
Primary CompletionMay 1, 2008
Study CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.8 years ago
Interventions
Atomoxetinedrug
Placebodrug